Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04631016 · ClinicalTrials.gov registry record · Phase 2

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

A Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
137
Enrollment target
20
Study locations

NCT04631016 is a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis that has completed, run by AstraZeneca. The registered enrollment target is 137 participants, below the 647-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04631016, a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
137 participants
Enrollment target
20
Study locations

Study Summary

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult participants with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.

Conditions Studied

Chronic Obstructive Pulmonary Disease (COPD) Chronic Bronchitis

Interventions

  • OTHER Placebo
  • DRUG Tozorakimab

Study Locations (20)

Other

  • Research Site - Nedlands
  • Research Site - South Brisbane
  • Research Site - Spearwood
  • Research Site - Tarragindi

Florida

  • Research Site - Kissimmee
  • Research Site - Ormond Beach
  • Research Site - Winter Park

South Carolina

  • Research Site - North Charleston
  • Research Site - Spartanburg

Alabama

  • Research Site - Sheffield

California

  • Research Site - Newport Beach

Delaware

  • Research Site - Newark

Kentucky

  • Research Site - Lakeside Park

Maryland

  • Research Site - White Marsh

Trial Details

FieldValue
Enrollment Target 137 participants
Start Date 2020-12-14
Est. Completion 2023-11-13
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04631016

The ClinicalTrials.gov registry entry for NCT04631016 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (79% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04631016 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Florida, South Carolina.

Frequently Asked Questions

What is clinical trial NCT04631016 about?

NCT04631016 is a clinical study titled "A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis". This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult participants with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.

What is the current status of trial NCT04631016?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2020-12-14. Estimated completion is 2023-11-13.

What conditions does trial NCT04631016 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis.

What interventions are being tested in trial NCT04631016?

The interventions under investigation include: Placebo (OTHER), Tozorakimab (DRUG).

Who is sponsoring clinical trial NCT04631016?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04631016 being conducted?

This trial has 20 study locations across Alabama, California, Delaware, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Obstructive Pulmonary Disease (COPD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Obstructive Pulmonary Disease (COPD)

All registered trials for this condition

Chronic Bronchitis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.